# Daunorubicin + Cytarabine + Venetoclax in de Novo AML

> **NCT06697327** · NA · ENROLLING_BY_INVITATION · sponsor: **Anhui Medical University** · enrollment: 94 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** (Daunorubicin, Cytarabine, Venetoclax)
- **DRUG:** (Daunorubicin, Cytarabine)

## Key facts

- **NCT ID:** NCT06697327
- **Lead sponsor:** Anhui Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-02-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06697327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06697327, "Daunorubicin + Cytarabine + Venetoclax in de Novo AML". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06697327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*